Adventrx Presents CoFactor Toxicity, Pharmacodynamics Data

Adventrx Pharmaceuticals has presented CoFactor toxicity and pharmacodynamics data collected from the company's ongoing CoFactor Phase II clinical trial in metastatic colorectal cancer.

The data suggest there is negligible risk of toxicity. C. Paul Spears, co-inventor of CoFactor, investigator in the COFU trial and lead author on the study, presented the results during the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.